Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 2, 2008, Pages 405-410

  Briz, Verónica ^a   Poveda, Eva ^a   Del mar gonzález, María ^a   Martín carbonero, Luz ^a   González gonzález, Rocío ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Entry inhibitors; HAART; Pathogenesis

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 7; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHENOTYPE; PREVALENCE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TROPISM;

EID: 38349189733     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm469     Document Type: Article

References (32)

1. Dragic T, Litwin V, Allaway G et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-73.
2. Feng Y, Broder C, Kennedy P et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-7.
3. Berger E, Doms R, Fenyö E et al. A new classification for HIV-1. Nature 1998; 391: 240.
4. Schuitemaker H, Kootstra N, de Goede R et al. Monocytotropic HIV-1 variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol 1991; 65: 356-63.
5. Shankarappa R, Margolick J, Gange S et al. Consistent viral evolutionary changes associated with the progression of HIV type 1 infection. J Virol 1999; 73: 10489-502.
6. Zhu T, Mo H, Wang N et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261: 1179-81.
7. Tersmette M, Gruters R, de Wolf F et al. Evidence for a role of virulent HIV variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates. J Virol 1989; 63 2118-25.
8. Koot M, Keet I, Vos A et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118: 681-8.
9. Schuitemaker H, Koot M, Kootstra N et al. Biological phenotype of HIV type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell tropic virus populations. J Virol 1992; 66: 1354-60.
10. Koot M, van Leeuwen R, de Goede R et al. Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of HIV type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999; 179: 254-8.
11. Poveda E, Briz V, Quinones-Mateu M et al. HIV tropism: Diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006; 20: 1359-67.
12. Guadalupe M, Reay E, Sankaran S et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary HIV type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Viro1 2003; 77: 11708-17.
13. Zaitseva M, Blauveli A, Lee S et al. Expression and function of CCR5 and CXCR4 on human Langerhans calls and macrophages: Implications for HIV primary infection. Nat Med 1997; 3: 1369-75.
14. Correa R, Munoz-Fernandez MA. Viral phenotype affects the thymic production of new T cells in HIV-1-infected children. AIDS 2001; 15: 1959-63.
15. Nishimura Y, Brown C, Mattapallil J et al. Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc Natl Acad Sci USA 2005; 102: 8000-5.
16. Fluur C, Rethi B, Thang P et al. Relationship between serum IL-7 concentrations and lymphopenia upon different levels of HIV immune control. AIDS 2007; 21: 1048-50.
17. Demarest J, Bonny T, Vavro C et al. HIV-1 co-receptor tropism in treatment naive and experienced subjects. In: Abstracts of the Forth-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract H-1136, p. 300. American Society for Microbiology, Washington, DC, USA.
18. Brumme Z, Goodrich J, Mayer H et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192: 466-74.
19. Moyle G, Wildfire A, Mandalia S et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191: 866-72.
20. Melby T, Despirito M, Demasi R et al. HIV-1 co-receptor tropism in triple-class-experienced patients: Baseline correlates and relationship to Enfuvirtide response. In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006. Abstract 233, p. 124. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
21. Wilkin T, Su Z, Kuritzkes D et al. Co-receptor tropism in patients screened for ACTG 5211, a Phase 2 study of Vicriviroc, a CCR5 inhibitor. In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006. Abstract 655, p. 283. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
22. Hunt P, Harrigan P, Huang W et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006; 194: 926-30.
23. Poveda E, Briz V, de Mendoza C et al. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. J Med Virol 2007; 79: 1040-6.
24. Jensen M, Li F, van't Wont A et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of HIV type 1 env V3 loop sequences. J Virol 2003; 77: 13376-88.
25. Labernardiere, J, Lebel-Binary S, Faudon J et al. Tropism determination and performance of Phenoscript HIV-1 entry inhibitors assay. Antivir Ther 2004; 9 Suppl: 141.
26. Samson M, Libert F, Doranz B et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-5.
27. De Mendoza C, Rodriguez C, Garcia F et al. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother 2007; 59: 698-704.
28. de Roda A, van Rij R, Blaak H et al. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for HIV type 1 disease progression. J Infect Dis 1999; 180: 1106-15.
29. Lehmann C, Däumer M, Boussaad I et al. Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART. J Clin Virol 2006; 37: 300-4.
30. Hunt P, Huang W, Coakley E et al. Longitudinal evaluation of viral co-receptor tropism switches among HIV-infected patients with drug resistant viremia. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 619, p. 294. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
31. Poveda E, Briz V, Roulet V et al. Correlation between a phenotypic assay and three bioinformatics tools for determining HIV co-receptor use. AIDS 2007; 21: 1487-90.
32. Skrabal K, Low A, Dong W et al. Is there a gold standard for determining HIV co-receptor use in clinical samples? The degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol 2007; 45: 279-84.